Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rostaporfin - Kintara Therapeutics

Drug Profile

Rostaporfin - Kintara Therapeutics

Alternative Names: PhotoPoint SnET2; Photrex; Purlytin; REM-001; REM-001 Therapy; Rostaporfin-PDT; Sn(IV) etiopurpurin; SnET2; SnET2-PDT; Tin ethyl etiopurpurin

Latest Information Update: 16 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kintara Therapeutics
  • Developer Kintara Therapeutics; Miravant Medical Technologies
  • Class Antiglaucomas; Antihyperlipidaemics; Antineoplastics; Antipsoriatics; Eye disorder therapies; Heavy metals; Mesoporphyrins; Vascular disorder therapies
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Basal cell nevus syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Basal cell cancer
  • No development reported Age-related macular degeneration
  • Discontinued Benign prostatic hyperplasia; Brain cancer; Coronary artery restenosis; Diabetic retinopathy; Glaucoma; Head and neck cancer; Kaposi's sarcoma; Lung cancer; Prostate cancer; Skin cancer

Most Recent Events

  • 14 Feb 2024 Clinical trials in Breast cancer (Metastatic disease) (unspecified route)
  • 12 Feb 2024 Kintara Therapeutics initiates phase II trial for Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (IV, infusion) (NCT05374915)
  • 28 Jun 2023 Kintara Therapeutics plans to restart clinical program for Cutaneous Metastatic Breast Cancer (CMBC) by the end of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top